Hodgkin Lymphoma (HL) is a common malignancy in adolescents. For relapsed/refractory disease many regimens have been proposed and novel agents are increasingly used. Brentuximab Vedotin (BV) is an antiCD30 antibody-drug conjugate used as single agent or in combination with classical regimens mainly in adults, while limited is the experience in paediatrics. We report here on two boys with aggressive and high-risk relapsed HL, successfully treated with the BV plus DHAP regimen as induction salvage treatment. Our experience provides initial real-world evidence on the use of BV-DHAP as first-line salvage therapy for high-risk relapsed/refractory HL and expands the current therapeutic choices.